Active Recombinant Human TIGIT Protein, His-tagged
Cat.No. : | TIGIT-104H |
Product Overview : | Recombinant Human TIGIT Protein extracellular domain 22-138aa (signal peptide removed), fused with a C-terminal His tag, was expressed in CHO. |
- Specification
- Gene Information
- Related Products
Description : | TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. |
Source : | CHO |
Species : | Human |
Tag : | His |
Predicted N Terminal : | Met 22 |
Form : | Lyophilized from sterile PBS, pH 7.4. |
Bio-activity : | Measured by its ability to bind with human CD155-Fc in a functional ELISA. Measured by its ability to bind with mouse PVRFch in a functional ELISA. |
Molecular Mass : | The recombinant mature human TIGIT protein consists of 123 amino acids and has a calculated molecular mass of 13.5 KD. |
Endotoxin : | <1.0EU/ug, LAL method |
Purity : | >95% (SDS-PAGE) |
Stability : | Samples are stable for up to twelve months from date of receipt at -70ºC. |
Storage : | Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | TIGIT T cell immunoreceptor with Ig and ITIM domains [ Homo sapiens ] |
Official Symbol : | TIGIT |
Synonyms : | TIGIT; T cell immunoreceptor with Ig and ITIM domains; V set and immunoglobulin domain containing 9 , V set and transmembrane domain containing 3 , VSIG9, VSTM3; T-cell immunoreceptor with Ig and ITIM domains; DKFZp667A205; FLJ39873; V-set and transmembrane domain containing 3; V-set and immunoglobulin domain containing 9; Washington University cell adhesion molecule; V-set and transmembrane domain-containing protein 3; V-set and immunoglobulin domain-containing protein 9; VSIG9; VSTM3; WUCAM; |
Gene ID : | 201633 |
mRNA Refseq : | NM_173799 |
Protein Refseq : | NP_776160 |
MIM : | 612859 |
UniProt ID : | Q495A1 |
Chromosome Location : | 3q13.31 |
Function : | protein binding; |
Products Types
◆ Recombinant Protein | ||
TIGIT-1089H | Recombinant Human TIGIT protein(Met22 - Pro141), His-tagged | +Inquiry |
Tigit-730M | Recombinant Mouse Tigit Protein | +Inquiry |
TIGIT-356H | Active Recombinant Human TIGIT Protein (Met22-Pro141, A103), C-Fc-tagged | +Inquiry |
TIGIT-727H | Recombinant Human TIGIT Protein | +Inquiry |
TIGIT-1037H | Recombinant Human TIGIT Protein, MYC/DDK-tagged | +Inquiry |
◆ Lysates | ||
TIGIT-1420MCL | Recombinant Mouse TIGIT cell lysate | +Inquiry |
TIGIT-2610HCL | Recombinant Human TIGIT cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionTIGIT inhibitors are being studied in a range of cancers, including lung cancer, breast cancer, and melanoma, among others.
TIGIT is being explored as a potential target for treating autoimmune diseases by modulating immune responses to prevent excessive inflammation.
TIGIT is being explored as a potential target for cancer immunotherapy, with drugs designed to block TIGIT and enhance the immune system's ability to attack cancer cells.
TIGIT operates as an immune checkpoint, similar to PD-1 and CTLA-4, but it has distinct mechanisms of action and may regulate different aspects of the immune response.
As with any immunotherapy, potential side effects may include immune-related adverse events such as inflammation in various organs, but the specific profile is still under investigation.
Customer Reviews (3)
Write a reviewWith its well-characterized nature and availability in various formats, the TIGIT protein is an advantageous tool that aids researchers in achieving their scientific goals.
Whether it's troubleshooting issues, optimizing experimental protocols, or providing detailed information about the protein, the manufacturer's support team is dedicated to helping researchers overcome any challenges they may encounter.
The manufacturer also ensures that the TIGIT protein is well-characterized, with extensive documentation on its functional properties.
Ask a Question for All TIGIT Products
Required fields are marked with *
My Review for All TIGIT Products
Required fields are marked with *
Inquiry Basket